An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated

Trial Profile

An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Fusidic acid (Primary)
  • Indications Bone and joint infections; Staphylococcal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Cempra Pharmaceuticals; Melinta Therapeutics
  • Most Recent Events

    • 06 Nov 2017 According to Melinta Therapeutics media release, Cempra Pharmaceuticals merged with Melinta Therapeutics to form Melinta Therapeutics.
    • 23 Jun 2017 Last checked against ClinicalTrials.gov record.
    • 19 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top